Your browser doesn't support javascript.
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.
Yu, Jingyou; Tostanoski, Lisa H; Mercado, Noe B; McMahan, Katherine; Liu, Jinyan; Jacob-Dolan, Catherine; Chandrashekar, Abishek; Atyeo, Caroline; Martinez, David R; Anioke, Tochi; Bondzie, Esther A; Chang, Aiquan; Gardner, Sarah; Giffin, Victoria M; Hope, David L; Nampanya, Felix; Nkolola, Joseph; Patel, Shivani; Sanborn, Owen; Sellers, Daniel; Wan, Huahua; Hayes, Tammy; Bauer, Katherine; Pessaint, Laurent; Valentin, Daniel; Flinchbaugh, Zack; Brown, Renita; Cook, Anthony; Bueno-Wilkerson, Deandre; Teow, Elyse; Andersen, Hanne; Lewis, Mark G; Martinot, Amanda J; Baric, Ralph S; Alter, Galit; Wegmann, Frank; Zahn, Roland; Schuitemaker, Hanneke; Barouch, Dan H.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Tostanoski LH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Mercado NB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • McMahan K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Liu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Jacob-Dolan C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Chandrashekar A; Harvard Medical School, Boston, MA, USA.
  • Atyeo C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Martinez DR; Harvard Medical School, Boston, MA, USA.
  • Anioke T; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Bondzie EA; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Chang A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Gardner S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Giffin VM; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Hope DL; Harvard Medical School, Boston, MA, USA.
  • Nampanya F; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Nkolola J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Patel S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Sanborn O; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Sellers D; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Wan H; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Hayes T; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Bauer K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Pessaint L; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Valentin D; Tufts University Cummings School of Veterinary Medicine, North Grafton, MA, USA.
  • Flinchbaugh Z; Tufts University Cummings School of Veterinary Medicine, North Grafton, MA, USA.
  • Brown R; Bioqual, Rockville, MD, USA.
  • Cook A; Bioqual, Rockville, MD, USA.
  • Bueno-Wilkerson D; Bioqual, Rockville, MD, USA.
  • Teow E; Bioqual, Rockville, MD, USA.
  • Andersen H; Bioqual, Rockville, MD, USA.
  • Lewis MG; Bioqual, Rockville, MD, USA.
  • Martinot AJ; Bioqual, Rockville, MD, USA.
  • Baric RS; Bioqual, Rockville, MD, USA.
  • Alter G; Bioqual, Rockville, MD, USA.
  • Wegmann F; Tufts University Cummings School of Veterinary Medicine, North Grafton, MA, USA.
  • Zahn R; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Schuitemaker H; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Barouch DH; Janssen Vaccines & Prevention, Leiden, The Netherlands.
Nature ; 596(7872): 423-427, 2021 08.
Article in English | MEDLINE | ID: covidwho-1279884
ABSTRACT
The emergence of SARS-CoV-2 variants that partially evade neutralizing antibodies poses a threat to the efficacy of current COVID-19 vaccines1,2. The Ad26.COV2.S vaccine expresses a stabilized spike protein from the WA1/2020 strain of SARS-CoV-2, and has recently demonstrated protective efficacy against symptomatic COVID-19 in humans in several geographical regions-including in South Africa, where 95% of sequenced viruses in cases of COVID-19 were the B.1.351 variant3. Here we show that Ad26.COV2.S elicits humoral and cellular immune responses that cross-react with the B.1.351 variant and protects against B.1.351 challenge in rhesus macaques. Ad26.COV2.S induced lower binding and neutralizing antibodies against B.1.351 as compared to WA1/2020, but elicited comparable CD8 and CD4 T cell responses against the WA1/2020, B.1.351, B.1.1.7, P.1 and CAL.20C variants. B.1.351 infection of control rhesus macaques resulted in higher levels of virus replication in bronchoalveolar lavage and nasal swabs than did WA1/2020 infection. Ad26.COV2.S provided robust protection against both WA1/2020 and B.1.351, although we observed higher levels of virus in vaccinated macaques after B.1.351 challenge. These data demonstrate that Ad26.COV2.S provided robust protection against B.1.351 challenge in rhesus macaques. Our findings have important implications for vaccine control of SARS-CoV-2 variants of concern.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunity, Humoral / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Immunity, Cellular / Macaca mulatta Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03732-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunity, Humoral / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Immunity, Cellular / Macaca mulatta Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03732-8